BPC-157 + TB-500 Blend: What the Fixed 5 mg : 5 mg Ratio Means in Practice

The 5 mg : 5 mg BPC + TB vial is the most-ordered blend in every wholesale code sheet — and the one most often mis-mathed in the hood. Here is the honest arithmetic.

What the vial actually is

One lyophilized cake containing both peptides at equal mass. Reconstituted to 2.0 mL bacteriostatic water, the vial holds 5 mg + 5 mg distributed in the same liquid: 2.5 mg/mL BPC-157 and 2.5 mg/mL TB-500 at every µL. There is no separation step; every draw carries both in 1:1 mass.

The reconstitution calculator handles the BPC side of the number exactly as for a single vial; then read the TB side off the same volume — the concentrations are equal by construction. For syringe work, the U-100 converter applies: at 2.5 mg/mL, 10 units (0.1 mL) carries 250 µg of each peptide.

Where the blend fits — and where it doesn’t

Fits: paired-pathway designs that want equimolar-mass co-exposure in one vessel, and where vial-count reduction matters (fewer openings, fewer contamination events, one batch to document).

Doesn’t fit: asymmetric designs. Much of the repair literature uses BPC at 2–10× the TB-500 mass per day — with a 1:1 blend that would over-deliver TB-500. Buy the separate vials and TB-500 for those.

Mechanism-level reasoning for the pairing — one peptide acting through growth-factor/NO signaling, the other through actin dynamics — is covered in the BPC-157 vs TB-500 comparison; storage and shipping match the components: −20 °C lyophilized, water-reconstitutable, shipped with one batch COA covering both actives.

For laboratory research use only. Not medical advice.